Loading organizations...
§ Private Profile · Tel Aviv, Israel
NeuraLight is a technology company.
NeuraLight develops a software-based platform that utilizes visual tasks and artificial intelligence to establish precise, scalable biomarkers for neurological conditions. This innovative approach integrates decades of neuroscience research, focusing on eye movements to translate performance data into quantifiable insights regarding brain function. The company’s technology provides an objective means to assess central nervous system activity.
The company was co-founded by Edmund Ben Ami, who serves as CEO, alongside scientific co-founders Gil Shklarski, PhD, and Nobel laureate Thomas C. Südhof, MD, PhD. This team brought together expertise in business, AI, and neuroscience, identifying an opportunity to leverage advanced technology to address the challenges of objective neurological assessment. Their collective insight aimed to transform subjective clinical observations into data-driven diagnostics.
NeuraLight collaborates with various partners in clinical settings globally, applying its platform to study a range of central nervous system diseases. The company’s overarching vision is to advance the field of neurology by providing tools that enhance diagnosis, monitoring, and treatment development for complex brain disorders. It aims to shape the future of neurological care through data-driven precision medicine.
NeuraLight has raised $56.0M across 3 funding rounds.
NeuraLight has raised $56.0M in total across 3 funding rounds.
NeuraLight has raised $56.0M across 3 funding rounds. Most recently, it raised $25.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 24, 2022 | $25M Series A | Koch Disruptive Technologies | Chris Mansi, David Golan, Lily Sarafan, Breyer Capital, Samsung Next, VSC Ventures | Announced |
| May 1, 2022 | $25M Seed | Koch Disruptive Technologies | Matias Ventures, MS&AD Ventures, Asaf Fybish, Fidji Simo, Lily Sarafan, Vivek Garipalli, Breyer Capital, Chris Mansi, David Golan, Samsung Next, VSC Ventures | Announced |
| Oct 1, 2021 | $6M Seed | — | 83North, AlleyCorp, Andreessen Horowitz, CVS Health, Echo Health Ventures, Felix Capital, Madrona Venture Group, Matias Ventures, MS&AD Ventures, Pitango Venture Capital, Sequoia Capital, Town Hall Ventures, Walden International, Dylan Field, Fidji Simo, Gokul Rajaram, Hadi Partovi, Lily Sarafan, Mike Vernal, Vivek Garipalli, Noam Solomon, Tamara Minick Scokalo, CrunchFund, KLI Capital, Operator Partners, VSC Ventures | Announced |
NeuraLight is a technology company specializing in the development of AI-powered platforms that analyze eye movements to provide objective biomarkers for central nervous system (CNS) diseases. Its product leverages computer vision and machine learning to extract precise ocular metrics from video data, enabling researchers and clinicians to monitor neurological disorders such as Parkinson’s, Alzheimer’s, Multiple Sclerosis, and ALS. The platform serves pharmaceutical companies and medical centers by enhancing drug development processes and clinical trial accuracy, ultimately aiming to accelerate neurological disease treatment advancements[1][2][3].
Founded in 2021, NeuraLight was co-founded by Micha Breakstone, previously the co-founder and president of Chorus.ai, and Edmund Benami, the CTO. Breakstone’s background in AI and software, combined with Benami’s technical expertise, fueled the vision to digitize neurological evaluation and care. The idea emerged from the need to develop more precise, scalable, and non-invasive biomarkers for neurological diseases, addressing the limitations of traditional clinical assessments. Early traction included securing $5.5 million in seed funding from notable investors and establishing dual headquarters in Austin and Tel Aviv, with partnerships in leading medical centers worldwide[2][3][4].
NeuraLight rides the growing trend of applying AI and digital biomarkers to healthcare, particularly in neurology, where objective and scalable disease monitoring tools are critically needed. The timing is favorable due to increasing investment in neurodegenerative disease research, the rise of telehealth, and the pharmaceutical industry's demand for better clinical trial endpoints. By providing a non-invasive, AI-driven solution, NeuraLight influences the broader ecosystem by enabling more efficient drug development and personalized patient care, potentially transforming neurological disease management[1][2][3].
Looking ahead, NeuraLight is positioned to expand its clinical partnerships and scale its oculometric database, enhancing AI-driven insights into neurological disorders. Trends such as remote patient monitoring, AI in healthcare, and personalized medicine will shape its trajectory. As the company matures, its influence may extend beyond drug development into routine clinical neurology practice, improving diagnosis and disease progression tracking. NeuraLight’s innovative approach to digitizing neurological evaluation could become a cornerstone technology in the fight against CNS diseases[2][3].
NeuraLight has raised $56.0M in total across 3 funding rounds.
NeuraLight's investors include Koch Disruptive Technologies, Chris Mansi, David Golan, Lily Sarafan, Breyer Capital, Samsung Next, VSC Ventures, Matias Ventures, MS&AD Ventures, Asaf Fybish, Fidji Simo, Vivek Garipalli.